UNASSIGNED: Objective To evaluate the outcomes of @entity263 with unfavorable prognostic factors treated with permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy.Methods From January 2003 to December 2008, 38 @entity1 classified as @entity263 with unfavorable prognostic factors were treated with trimodality therapy (brachytherapy + external radiotherapy + hormone therapy). The prescription dose of brachytherapy and external radiotherapy were 110 Gy and 45 Gy, respectively. The duration of hormone therapy was 2-3 years. The endpoints of this study included biochemical failure-free survival (BFFS), distant @entity3 -free survival (DMFS), @entity5 -specific survival (CSS), and @entity1349 ( @entity1349 ). Survival curves were calculated using the Kaplan-Meier method. The Log-rank test was used to identify the prognostic predictors for univariate analysis.Results The median follow-up was 71 months. The serum pre-treatment @entity1486 (PSA) level ranged from 10.0 to 99.8 ng/ml (mean 56.3 ng/ml), the Gleason score ranged from 5 to 9 (median 8), and the percentage of positive biopsy cores ranged from 10% to 100% (mean 65%). The 5-year BFFS, DMFS, CSS, and @entity1349 rates were 44%, 69%, 82%, and 76%, respectively. All biochemical failures occurred within 40 months. The percentage of positive biopsy cores was significantly correlated with BFFS, DMFS, and @entity1349 (all P=0.000), and the Gleason score with DMFS (P=0.000) and @entity1349 (P=0.001).Conclusions @entity263 with unfavorable prognostic factors presents not so optimistic outcome. Hormone therapy should be applied to prolong the biochemical progression-free or @entity3 -free survival. The percentage of positive biopsy cores and the Gleason score are significant prognostic factors.

Outcomes of T3a XXXX with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['T3a prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
